サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1768680

尿路上皮がん治療薬の世界市場：タイプ別、治療別、エンドユーザー別、地域別、機会、予測、2018年～2032年

Global Urothelial Cancer Drugs Market Assessment, By Type, By Treatment, By End-user, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 232 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
尿路上皮がん治療薬の世界市場：タイプ別、治療別、エンドユーザー別、地域別、機会、予測、2018年～2032年
出版日: 2025年07月11日
発行: Markets & Data
ページ情報: 英文 232 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の尿路上皮がん治療薬市場は、2025～2032年の予測期間中にCAGR 9.12％を記録し、2024年の30億3,000万米ドルから2032年には60億9,000万米ドルに成長すると予測されています。世界の尿路上皮がん治療薬市場は、尿路上皮がんの有病率の増加、免疫療法と標的療法の急速な採用、強力な研究開発投資、早期診断に対する意識の高まり、医療インフラの改善、有利な規制当局の支援によって牽引され、これらは世界中でより良い治療選択肢と患者転帰の改善に寄与しています。

世界の尿路上皮がん治療薬市場は、免疫療法の複数の進歩、さまざまな戦略的提携、市場への医療投資の増加により急速に拡大しています。免疫チェックポイント阻害薬を含む併用療法などの新しい治療法は、筋層非浸潤性膀胱がんの治療に革命をもたらし、患者の転帰を改善し、世界中で市場機会をもたらしています。

例えば、2025年4月には、European Urology Oncology誌が筋層浸潤性膀胱がんに対する免疫チェックポイント阻害薬に関するレビューを発表しました。このレビューでは、免疫療法の進歩と治療選択肢の進化に牽引された市場の急速な成長が強調されました。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の尿路上皮がん治療薬市場の展望、2018年～2032年

  • 市場規模分析と予測
    • 金額別
  • 市場シェア分析と予測
    • タイプ別
      • 尿路上皮がん
      • 扁平上皮がん
      • 腺がん
    • 治療別
      • 化学療法
      • 免疫療法
      • 標的療法
      • 併用薬物療法
    • エンドユーザー別
      • 病院
      • がん治療センター
      • 外来手術センター
      • その他
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社・その他- 金額別、2024年）
  • 2024年市場マップ分析
    • タイプ別
    • 治療別
    • エンドユーザー別
    • 地域別

第6章 北米の尿路上皮がん治療薬市場の展望、2018年～2032年

  • 市場規模分析と予測
    • 金額別
  • 市場シェア分析と予測
    • タイプ別
      • 尿路上皮がん
      • 扁平上皮がん
      • 腺がん
    • 治療別
      • 化学療法
      • 免疫療法
      • 標的療法
      • 併用薬物療法
    • エンドユーザー別
      • 病院
      • がん治療センター
      • 外来手術センター
      • その他
    • 国別シェア
      • 米国
      • カナダ
      • メキシコ
  • 国別市場評価
    • 米国の尿路上皮がん治療薬市場の展望、2018年～2032年
      • 市場規模分析と予測
      • 市場シェア分析と予測
    • カナダ
    • メキシコ

第7章 欧州の尿路上皮がん治療薬市場の展望、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の尿路上皮がん治療薬市場の展望、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の尿路上皮がん治療薬市場の展望、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの尿路上皮がん治療薬市場の展望、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 輸出入分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場促進要因
  • 市場の課題

第17章 市場動向と発展

第18章 規制枠組みとイノベーション

  • 規制当局の承認
  • 臨床試験

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

  • 市場リーダー上位5社の競合マトリックス
  • トップ5社のSWOT分析
  • 市場トップ10社の主要企業の情勢
    • Pfizer, Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • F. Hoffmann La Roche Ltd.
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Sanofi SA
    • Eisai Co. Ltd.
    • Merck KGaA
    • UroGen Pharma, Inc.

第22章 戦略的提言

第23章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 3. Global Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 4. Global Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 5. Global Urothelial Cancer Drugs Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 8. North America Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 9. North America Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 10. North America Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 13. United States Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 14. United States Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 15. Canada Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 17. Canada Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 18. Canada Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 19. Mexico Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 21. Mexico Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 22. Mexico Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 23. Europe Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 25. Europe Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 26. Europe Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 27. Europe Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 30. Germany Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 31. Germany Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 32. France Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 34. France Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 35. France Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 36. Italy Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 38. Italy Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 39. Italy Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 40. United Kingdom Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 42. United Kingdom Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 43. United Kingdom Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 44. Russia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 46. Russia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 47. Russia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 48. Netherlands Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 50. Netherlands Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 51. Netherlands Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 52. Spain Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 54. Spain Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 55. Spain Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 56. Turkey Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 58. Turkey Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 59. Turkey Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 60. Poland Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 62. Poland Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 63. Poland Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 64. South America Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 66. South America Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 67. South America Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 68. South America Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 71. Brazil Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 72. Brazil Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 73. Argentina Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 75. Argentina Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 76. Argentina Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 77. Asia-Pacific Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 79. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 80. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 81. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 82. India Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 84. India Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 85. India Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 86. China Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 88. China Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 89. China Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 90. Japan Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 92. Japan Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 93. Japan Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 94. Australia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 96. Australia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 97. Australia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 98. Vietnam Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 100. Vietnam Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 101. Vietnam Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 102. South Korea Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 104. South Korea Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 105. South Korea Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 106. Indonesia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 108. Indonesia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 109. Indonesia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 110. Philippines Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 112. Philippines Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 113. Philippines Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 114. Middle East & Africa Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 116. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 117. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 118. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 121. Saudi Arabia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 122. Saudi Arabia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 123. UAE Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 125. UAE Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 126. UAE Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 127. South Africa Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 129. South Africa Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 130. South Africa Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 131. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13613

Global urothelial cancer drugs market is projected to witness a CAGR of 9.12% during the forecast period 2025-2032, growing from USD 3.03 billion in 2024 to USD 6.09 billion in 2032. The global urothelial cancer drug market is driven by the increasing prevalence of urothelial cancers, rapid adoption of immunotherapy and targeted therapies, strong R&D investments, rising awareness for early diagnosis, improved healthcare infrastructure, and favorable regulatory support, which are contributing to better treatment options and improved patient outcomes worldwide.

The global urothelial cancer drug market is expanding rapidly due to multiple advances in immunotherapy, a variety of strategic partnerships, and an increase in healthcare investment in the market. New therapies, such as combination therapy that involves immune checkpoint inhibitors, are revolutionizing the treatment of non-muscle invasive bladder cancer and improving patient outcomes and providing market opportunities across the globe.

For instance, in April 2025, European Urology Oncology published a review on immune checkpoint inhibitors for muscle-invasive bladder cancer. This highlighted rapid market growth fueled by advances in immunotherapy and evolving treatment options.

Increased Incidence Accelerates Growth in Urothelial Cancer Drug Market

Urothelial cancer incidence is on the rise and this in turn is affecting the urothelial cancer drugs market globally. As more people are diagnosed every year, many of whom are attributable to the aging population, smoking and environmental risk factors, the demand for products, either new products or improvements on existing products, is increasing rapidly. A target patient population that continues to flourish is pushing pharmaceutical companies to hasten research and development for identifying therapeutic targets and devising novel immunotherapies to address emerging clinical needs. Additionally, the healthcare system is under pressure to take on any new drug that will increase survival and quality of life for the emerging patient population.

For instance, according to the American Cancer Society, in 2025, there were projected to be 84,870 new cases of bladder cancer in the United States (about 65,080 in men and 19,790 in women) along with approximately 17,420 deaths, underscoring the growing need for effective urothelial cancer treatments.

Therapeutic and Diagnostic Advancement Fuel Urothelial Cancer Drug Market Growth

The global urothelial cancer drug market remains in growth, primarily due to improvements in treatment and discovery for urothelial cancer. Precision therapies and state-of-the-art diagnostics are evolving the entire industry landscape to improve outcomes and create a new vantage point for reasons for adoption. Targeted treatments such as FGFR inhibitors offer personalized treatments for patients identified with inherited genetic alterations to address their cancer, while immunotherapy combinations are increasingly replacing frontline therapies due to their superior outcomes relative to traditional chemotherapy. Simultaneously, novel non-invasive diagnostic tools, such as urine-based genomic assays, demonstrate unprecedented accuracy in early malignancy detection. This advancement improves treatment options and enables proactive care planning, while expanding market opportunities through earlier intervention. In sum, all these advances are expanding the population of patients that can be addressed and driving demand for advanced therapeutic agents globally.

For instance, in May 2025, the Scottish Medicines Consortium (SMC) approved BALVERSA (erdafitinib), marking a major milestone as the first licensed bladder cancer therapy to specifically target FGFR3 alterations.

Immunotherapy Leads the Global Urothelial Cancer Drug Market

Immunotherapy has become the dominant segment of the global urothelial cancer drugs market, revolutionizing treatment paradigms by harnessing the immune system to target cancer cells more effectively and with reduced toxicity compared to conventional therapies. This utilizes patient outcomes to improve where previous therapies have failed. The presence of an ever-growing pipeline of immunotherapeutic and continued regulatory approvals provides significant growth in the market and attracts significant capital as well as innovation. Immunotherapy is competitive and disruptive in ways that hospitals and medical professionals did not expect. In addition to changing treatment modalities, many treatments extend life and improve quality of life, which in turn towards personalized cancer care, or care that is specific to a patient's unique situation.

For instance, in April 2024, ImmunityBio launched ANKTIVA (nogapendekin alfa inbakicept), a first-in-class IL-15 receptor agonist, after receiving FDA approval for the treatment of BCG-unresponsive non-muscle invasive urothelial cancer.

North America Dominates the Urothelial Cancer Drugs Market Size

North America, especially the United States, is the largest geographic area for the global urothelial cancer drugs market, due to an innovative healthcare system with early adoption of new therapies and a very conducive regulatory environment for good clinical practice. In addition, the North America urothelial cancer drugs market is projected to surge owing to the existence of pharmaceutical companies, specialty oncology care is widely available, ample research funding is available, and innovators have and continue to develop treatment options, coupled with easy accessibility of advancing bladder cancer care. Regulatory authorities, such as the US Food and Drug Administration (FDA), also have a major impact on the rate of innovations, regularly using accelerated approval pathways for innovative immunotherapies and targeted drugs through various priority review designations. This expedited access to innovation in the United States market will translate to first access for clinicians to innovative therapies globally as they will enter practice sooner.

For example, in March 2024, the FDA approved nivolumab (Opdivo) in combination with cisplatin and gemcitabine for first-line treatment of adults with unresectable or metastatic urothelial carcinoma. This approval, based on the large CheckMate 901 Phase III trial, was granted priority review and introduced the first immunotherapy plus chemotherapy regimen into standard care.

Impact of U.S. Tariffs on Global Urothelial Cancer Drugs Market

Rising Manufacturing Costs: Tariffs on the APIs and finished drugs used to produce oral cancer treatments raise the manufacturing costs.

Rising Drug Prices: Patients and payers will be faced with increased costs of the treatments because of the increased manufacturing costs likely to be passed along to them.

Increased Pressure on Generic Drug Access: Generic producers operate at very limited margins and may respond by cutting back on the amount of drugs they produce or, more problematically, not producing the drugs at all, reducing access to the drugs.

Supply Chain Disruption: Import dependence means tariffs will have an impact on supply chains and possibly shortages and delays.

Time Delay on the Domestic Manufacturing Response: Building new manufacturing facilities takes multiple years, and tariffs are a short-term solution.

Restricted Patient Access: Increased prices mean that access to treatment is affected, particularly for low-income or uninsured patients.

Impact on Clinical Trial Research: Instability in drug supply can slow down or disrupt clinical research on oral medications due to difficulty accessing consistent supplies.

Key Players Landscape and Outlook

Growing the global urothelial cancer drugs market are the major pharmaceutical companies who are utilizing innovative therapies, collaborations and personalized models of treatment. The top leaders in the field are manipulating non-invasive treatment options along with immunotherapy and combination treatment options to address early treatment and resistant urothelial cancers. Companies are also responding to the unmet need of patients with non-muscle invasive bladder cancer with options that are non-invasive intravesical therapies. By forming partnerships, licensing arrangements, or co-development and agreements, these companies are expediting innovations in urothelial cancers and delivering to many regions of the world. These strategies are enhancing patient outcomes and changing current treatment options.

For example, in April 2025, Pfizer, Inc. announced that its immunotherapy drug sasanlimab, combined with BCG, significantly improved event-free survival in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, demonstrating how targeted innovation by key players is driving market growth and advancing care standards.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Urothelial Carcinoma
      • 5.2.1.2. Squamous Cell Carcinoma
      • 5.2.1.3. Adenocarcinoma
    • 5.2.2. By Treatment
      • 5.2.2.1. Chemotherapy
      • 5.2.2.2. Immunotherapy
      • 5.2.2.3. Targeted Therapy
      • 5.2.2.4. Combination Drug Therapy
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Cancer Treatment Centers
      • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Type
    • 5.3.2. By Treatment
    • 5.3.3. By End-user
    • 5.3.4. By Region

6. North America Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Type
      • 6.2.1.1. Urothelial Carcinoma
      • 6.2.1.2. Squamous Cell Carcinoma
      • 6.2.1.3. Adenocarcinoma
    • 6.2.2. By Treatment
      • 6.2.2.1. Chemotherapy
      • 6.2.2.2. Immunotherapy
      • 6.2.2.3. Targeted Therapy
      • 6.2.2.4. Combination Drug Therapy
    • 6.2.3. By End-user
      • 6.2.3.1. Hospitals
      • 6.2.3.2. Cancer Treatment Centers
      • 6.2.3.3. Ambulatory Surgical Centers
      • 6.2.3.4. Others
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Urothelial Cancer Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Type
          • 6.3.1.2.1.1. Urothelial Carcinoma
          • 6.3.1.2.1.2. Squamous Cell Carcinoma
          • 6.3.1.2.1.3. Adenocarcinoma
        • 6.3.1.2.2. By Treatment
          • 6.3.1.2.2.1. Chemotherapy
          • 6.3.1.2.2.2. Immunotherapy
          • 6.3.1.2.2.3. Targeted Therapy
          • 6.3.1.2.2.4. Combination Drug Therapy
        • 6.3.1.2.3. By End-user
          • 6.3.1.2.3.1. Hospitals
          • 6.3.1.2.3.2. Cancer Treatment Centers
          • 6.3.1.2.3.3. Ambulatory Surgical Centers
          • 6.3.1.2.3.4. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Import Export Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Regulatory Approvals
  • 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Pfizer, Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. GlaxoSmithKline plc
    • 21.3.3. Novartis AG
    • 21.3.4. F. Hoffmann La Roche Ltd.
    • 21.3.5. Astellas Pharma Inc.
    • 21.3.6. AstraZeneca plc
    • 21.3.7. Sanofi SA
    • 21.3.8. Eisai Co. Ltd.
    • 21.3.9. Merck KGaA
    • 21.3.10. UroGen Pharma, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer